Intas Pharmaceuticals

Intas Pharmaceuticals is a multinational pharmaceutical organization that has achieved substantial growth, reaching a revenue of over $2.5 billion with a 19% CAGR. Operating in 85+ countries, with the majority of revenue generated from global business, the company has positioned itself as a leader in the industry. It's the largest privately owned Indian generic pharma company and holds a significant ranking within the Indian pharmaceutical market. Recognized for its expertise in therapeutic segments like CNS, Cardio, Diabeto, Gastro, Urology, Oncology & Animal Health in India, Intas has also solidified its position among the top 10 generic players in the highly regulated markets of EU, US & UK. The company operates 16 advanced formulations, R&D, and distribution facilities worldwide, with accreditation from global regulators such as USFDA, EMA, MHRA, TGA, and others. With a substantial investment in R&D, Intas boasts over 10,000 product registrations worldwide and a strategic pipeline of 300+ high-value FTF/FTM, Biosimilars, and NDDS products. Its advanced EU-GMP Certified Biopharma division focuses on providing affordable “Biosimilars for Billions” across various niche segments. Furthermore, its Plasma Fractionation Unit is a pioneer in manufacturing plasma-derived therapeutics, supported by a full-fledged R&D lab and a state-of-the-art WHO-GMP-certified manufacturing facility. Established in 2000 and headquartered in India, Intas Pharmaceutical's commitment to values such as Innovation, Customer Delight, Ownership & Collaboration, Performance Focus & Care for Society drive the company towards excellence. The latest investment on 10 October 2022 was a Secondary Market investment by the Abu Dhabi Investment Authority. With its impressive track record, extensive global presence, and focus on innovation, Intas Pharmaceuticals represents an appealing opportunity for venture capital.